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Sclerostin antibodyType 1 diabetes mellitus (T1DM) patients have osteopenia and impaired fracture healing due to decreased oste-
oblast activity. Further, no adequate treatments are currently available that can restore impaired healing in
T1DM; hence a signiﬁcant need exists to investigate new therapeutics for treatment of orthopedic complications.
Sclerostin (SOST), a WNT antagonist, negatively regulates bone formation, and SostAb is a potent bone anabolic
agent. To determine whether SOST antibody (SostAb) treatment improves fracture healing in streptozotocin
(STZ) induced T1DMmice, we administered SostAb twice weekly for up to 21 days post-fracture, and examined
bone quality and callus outcomes at 21 days and 42 days post-fracture (11 and 14 weeks of age, respectively).
Here we show that SostAb treatment improves bone parameters; these improvements persist after cessation
of antibody treatment. Markers of osteoblast differentiation such as Runx2, collagen I, osteocalcin, and DMP1
were reduced, while an abundant number of SP7/osterix-positive early osteoblasts were observed on the bone
surface of STZ calluses. These results suggest that STZ calluses have poor osteogenesis resulting from failure of os-
teoblasts to fully differentiate and produce mineralized matrix, which produces a less mineralized callus. SostAb
treatment enhanced fracture healing in both normal and STZ groups, and in STZ+ SostAbmice, also reversed the
lowermineralization seen in STZ calluses. Micro-CT analysis of calluses revealed improved bone parameters with
SostAb treatment, and themineralized bone was comparable to Controls. Additionally, we found sclerostin levels
to be elevated in STZmice and β-catenin activity to be reduced. Consistent with its function as aWNT antagonist,
SostAb treatment enhanced β-catenin activity, but also increased the levels of SOST in the callus and in circula-
tion. Our results indicate that SostAb treatment rescues the impaired osteogenesis seen in the STZ induced
T1DM fracture model by facilitating osteoblast differentiation and mineralization of bone.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type 1 diabetes mellitus (T1DM) patients develop osteopenia,
which increases the risk of fractures; additionally, these fractures are
more likely to result in delayed or impaired healing, caused by reduced
bone formation [1–6]. Fracture risk and the risk of osteoporosis increase
with age, length of time after diagnosis, and with complications such as
kidney disease [7]. Recent studies have shown that the lowbonemass in
T1DM is mild, and caused by reduced osteoblast activity [3,8]. Although
some studies show association of T1DM and increased osteoclast activ-
ity [9,10], others fail to show any changes in resorption [2,11]. In con-
trast, some Type 2 diabetes mellitus (T2DM) patients have an increase
in bone mineral density [12,13], however, similar to T1DM, T2DM pa-
tients are also more likely to develop fracture healing complications,. This is an open access article undersuggesting a shared mechanism that contributes to the impaired frac-
ture healing associated with diabetic bone repair [12,14].
Glucose control, although important for treatment, does not provide
universal protection from the downstream effects of diabetes. The at-
tachment of glucose moieties (glycation) that interfere with protein
and tissue structure and function can be reduced but not prevented
[15]. Glycation of Type I collagen in bone reduces the ability of osteo-
blasts to adhere to the extracellular matrix and diminishes alkaline
phosphatase (bone-forming) activity. In T1DM rat models, closed frac-
tures showed a delay in healing time in both insulin-controlled and un-
controlled groups [16], which is consistent with human patients [17].
Although insulin control of blood glucose levels is an integral part of
T1DM treatment, it cannot completely correct the bone loss [18], or
the delayed fracture healing in T1DM; an additional therapeutic inter-
vention is needed.
CanonicalWNT signaling, which relies on β-catenin activity, in addi-
tion to its many roles during embryonic development [19–21], is alsothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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treat diabetic fractures. In TCF reporter mice, a LacZ gene is expressed
upon β-catenin activation and TCF binding, thus providing a way to as-
sess canonical WNT signaling activity. After closed tibial fracture in
mice, reporter activity indicated that elevated β-catenin signaling is
sustained during the entire time course of fracture repair [22]. Further-
more, β-catenin hyperactivity during fracture repair improved fracture
healing evenwhen increased in osteoblast cells only [22]. β-Catenin ac-
tivation is a requirement for mesenchymal stem cell differentiation into
osteoblasts and osteoblast maturation; lack of β-catenin in mice results
in decreased bone density [23]. Type 1 diabetic rats showed a decrease
in the WNT downstream effectors phosphorylated glycogen synthase
kinase 3β (GSK3β) and activated β-catenin, along with an increase in
SOST protein level, which resulted in decreased osteoblast activity [11].
In addition, T2DM patients have elevated circulating SOST levels com-
pared with non-diabetic patients [24], suggesting that WNT signaling
is altered and may contribute to the observed osteopenia and delayed
healing. Taken together, these data suggest that a high blood glucose en-
vironment alters osteoblast activity via WNT signaling.
To modulate WNT signaling, we have targeted sclerostin (SOST), a
potent WNT antagonist secreted by osteocytes, which functions to in-
hibit bone formation [25]. In animal models, overexpression of SOST
causes osteopenia and limb defects [26,27], while lack of SOST causes
3–4 times more bone mass, consistent with human phenotypes [28,
29]. In humans, lack of sclerostin causes sclerosteosis, a generalized
skeletal hyperostosis disorder that results from elevated WNT signal-
ing/osteoblast activity [30,31], while non-coding deletions of gene reg-
ulatory regions that control SOST expression result in similar bone
overgrowth [28,32]. SOST antibodies (SostAb) have been shown to en-
hance bone healing in ovariectomized rats [33,34] by increasing bone
formation and mass due to enhanced osteoblast function. SostAb treat-
ment in T2DM rat models has also been shown to improve bone mass
and strength [35].
In this study, we have administered SOST-neutralizing antibodies
in vivo, in a pharmacological model of T1DM inmice during fracture re-
pair. By enhancing canonical WNT signaling, we have shown improved
fracture repair and rescued the osteopenia in T1DMmice. The improved
bone quality persisted at least three weeks after treatment had been
discontinued, suggesting an extended beneﬁt to bone quality and frac-
ture repair in the absence of glucose control. In addition, T1DM in our
model induced enhanced bone marrow adipogenesis, which was res-
cued in healing fractures by SostAb treatment. Herein we demonstrate
for the ﬁrst time that sclerostin antibodies counteract effects of high
glucose-driven elevation of SOST levels in uncontrolled diabetes, indi-
cating a positive therapeutic effect of modulating WNT signaling in
T1DM patients.
2. Methods
2.1. Animals and fracture model
Six-week old C57BL6/J male mice were injected daily with
streptozotocin (STZ) (50 mg/kg) or phosphate buffered saline
(PBS) for 5 days; diabetic status was conﬁrmed by blood glucose
readings of ≥300 mg/dL, one week after the last injection. At eight
weeks of age, mid-femoral fractures were generated using a closed
Einohorn model as previously described [36]. SOST antibody,
(SostAb; Regeneron) (25 mg/kg), or PBS was administered subcuta-
neously twice weekly up to 21 days post-fracture or 11 weeks of age,
for a total of ﬁve injections, in Control, STZ, SostAb, and STZ + SostAb
groups; age-matched, uninjured cohorts (n = 6–10 per group per
time point) were also treated. At 21 days and 42 days post-fracture,
bones were dissected and processed for microscale-computed to-
mography (μCT), histology and immunoﬂuorescence (IF). All animal
work was IACUC-approved and performed at Lawrence Livermore
National Laboratory in an AAALAC-accredited facility.2.2. Histology and immunoﬂuorescent staining
Collected tissueswere ﬁxed, dehydrated, embedded and sectioned as
described previously [28]. For histology, slides were stained with Alcian
Blue pH 1.5 and Nuclear Fast Red, or Masson's Trichrome. For
immunoﬂuorescence, Uni-trieve (Innovex) was used for the antigen
retrieval for 30min at 65 °C, unless stated otherwise. Primary antibodies
against Runx2 (abcam, ab76956), collagen Type 1 (calbiochem 234167),
SP7/Osterix (ab22522), osteocalcin (abcam, ab10911), active caspase 3
(cellsig 9661), were used. Anti-SOST (R&D, AF1589) required Trypsin/
EDTA at 37 °C for 25 min for antigen retrieval. Anti-activated β-catenin
(Millipore, 8E7, 05-665) required Uni-trieve, Proteinase K (15 μg/mL)
for 15 min, and Rodent Block. Secondary antibodies (Alexa Fluor 488
(green) or 594 (red), Molecular Probes) were used for detection. Nega-
tive control slides included secondary antibody-only, with the same an-
tigen retrievalmethod used for the experimental samples (see also Supp.
Fig. 2). Stained slides were mounted with Prolong Gold with DAPI (Mo-
lecular Probes). ImagePro Plus V7.0 software and a QIClick CCD camera
were used for imaging. Qualitative assessment of immunostainswas per-
formed by 2 blinded reviewers without knowledge of treatment group.
For histological analysis of adipocytes and osteoclasts, cellswere counted
on complete bone sagittal sections (n= 12 sections per animal) for n=
3 animals per group by two blinded reviewers. Counts by each reviewer
were averaged on a per-section basis for analysis. Cells were counted by
hand for adipocytes, as they are represented by clear round empty spaces
on the slide. Data are expressed as mean number of cells per section ±
standard deviation. Cathepsin K immunostains were quantiﬁed using
the Analyze Particles tool in ImageJ. Data are expressed as mean %
stained area ± standard deviation.2.3. Micro-CT
Specimens were stored in 70% EtOH at 4 °C. Specimenswere proc-
essedwithout knowledge of sex, age or treatment, as these data were
provided only after all the scanning and image analyses were com-
plete. L4 vertebrae, mid-femoral cortical bone, and fracture callus
were measured and analyzed for bone parameters (n = 6–10 per
group) (μCT 40, Scanco, Brüttisellen, Switzerland) according to the
guidelines for μCT analysis of rodent bone structure [37]: energy
55 kVp, intensity 114 mA, integration time 900 ms, 6 μm nominal
voxel size. The threshold for “bone”was set at 375, which is approx-
imately equal to 620 mg HA/cm3. The trabecular bone region was
identiﬁed manually by tracing the region of interest. Images were
thresholded using an adaptive–iterative algorithm and morphomet-
ric variables were computed from the binarized images using direct,
3D techniques that do not rely on any prior assumptions about the
underlying structure. L4 vertebrae were scanned axially in a cranio-
caudal orientation and the region of interest was placed 0.3 mm be-
neath the cranial and above the caudal growth plates [38]. Depend-
ing on the size of the vertebra, this ROI size ranged between 2220
and 2820 μm. 7 images were segmented with the same algorithm
and trabecular bone variables were assessed. To assess cortical
bone parameters, 50 transverse μCT slices were obtained at the
femoral mid-diaphysis using a 6 μm isotropic voxel size. Images
were subjected to Gaussian ﬁltration and segmented using a con-
stant threshold. For fracture analysis, age-matched animals (11 or
14-weeks of age) were compared with 21 day or 42 day fractures
for cortical measurements. Callus volume (TV) was measured in-
cluding only callus tissue that excluded the native bone volume of
the original cortical bone and marrow space. The whole callus was
scanned, and wemanually drew the contour line to deﬁne the region
and volume of callus (TV). Then we used a uniﬁed threshold to seg-
ment mineralized callus from surrounding undermineralized callus,
and only the callus that had similar BMD as native bone was counted
into bone volume (BV).
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A mouse sclerostin ELISA kit (ALPCO, 41-SCLMS-E01) was used ac-
cording to the manufacturer's instructions to measure serum sclerostin
levels. Data is represented as mean ± standard deviation (n = 5 per
group).3. Statistics
All data were expressed as the mean ± standard deviation. For uCT
and quantitative histological analyses, two-way ANOVAwas performed
with Sidak's correction for multiple comparisons using PRISM 6 soft-
ware. Signiﬁcant results are presented as a diabetic effect, antibody
treatment effect, or diabetic × antibody treatment interaction effect;
p b 0.05 was considered signiﬁcant. For statistical analysis of SOST
ELISA results, Student's t-test with a two-tailed distribution was used,
with two-sample equal variance (homoscedastic test), for signiﬁcance.
All groups were compared with Control; p b 0.05 was considered
signiﬁcant.4. Results
4.1. SostAb improves loss of bone in uninjured STZ mice
The experimental design included two collection time points at
11 weeks and 14 weeks of age, for uninjured age-matched cohorts;
SostAb was discontinued after 3 weeks of treatment or 11 weeks of
age (Fig. 1A). At 11 weeks of age, STZ-treated mice (STZ) showed ab-
normal growth plates, with reduced trabecular bone and less orga-
nized cartilage matrix deposition in the growth plate (Fig. 1D,
yellow arrowheads), compared with Controls (Figs. 1B, D). We also
noted an increase in adipocytes in the bone marrow of STZ-treated
mice, (Figs. 1D,H, black arrowheads), as well as reduced trabecular
bone (Figs. 1F, H), supporting previous reports of bone loss in STZ-
treated animals [40,41]. All groups showed increased trabecular
bone in the metaphysis, in comparison with STZ, which showed
less trabecular bone (Figs. 1B–E, and yellow arrowheads), STZ +
SostAb also appeared to have a more organized growth plate (Figs.
1D,E). SostAb treatment dramatically increased trabecular bone for-
mation in the epiphysis (Figs. 1F–H). Cortical bone was much thicker
in SostAb-treated groups (Figs. 1J–M, arrows), and while STZ mice
showed residual cartilage matrix in the cortical bone (Fig. 1L, arrow-
head) SostAb treatment of STZ mice resulted in less persistent carti-
lage (Fig. 1M).
μCT analysis reveals that uninjured STZ mice had signiﬁcantly re-
duced bone volume to total bone volume ratio (BV/TV), trabecular thick-
ness (Tb. Th.), and Structural Model Index (SMI) in lumbar vertebrae
(L4) as a result of the diabetic state (Table 1, see also Figs. 1N,P). In cor-
tical bone, bone area: total area (BA/TA) (p b 0.0001), bonearea (BA) (p b
0.0001), and total area (TA) are reduced in uninjured STZmice compared
with Control (Table 1, see also Figs. 1R,T). No changes were identiﬁed in
connectivity density (Conn. dens.), trabecular number (Tb. N.), trabecu-
lar separation (Tb. Sp.) or bone mineral density (BMD). SostAb-treated
mice, both with and without diabetes, had a signiﬁcant improvement
in all bone parameters except L4 BMD in L4 vertebrae (Table 1, see
also Figs. 1N,O). In cortical bone, SostAb-treatedmice, with orwithout di-
abetes, had signiﬁcantly increased BA/TA (p b 0.0001) and BA (Table 1,
see also Figs. 1R,S). In STZ + SostAb-treated mice, BV/TV, SMI, and Tb.
Th. (all p b 0.0001), showed signiﬁcant diabetes× antibody treatment in-
teractions, suggesting that the effect of antibody treatment in
diabetic animals may provide synergistic improvement for these
parameters. Overall, our data from uninjured animals at 11 weeks
of age indicates that SostAb improves diabetic osteopenia in the
absence of fracture.4.2. Improved bone parameters persist 3-weeks after discontinuation of
SostAb treatment in uninjured STZ mice
To examine whether diabetic bone reverts to the osteopenic condi-
tion subsequent to SostAb treatment discontinuation, we examined
bone parameters in 14-week old uninjured cohorts, or 3-weeks after ces-
sation of SostAb treatment. We found no signiﬁcant effect of diabetes on
the variance in STZmice, however, the means for all parameters in lum-
bar vertebrae were signiﬁcantly different from Controlmice (p b 0.0001
for all parameters) (Table 2, see also Figs. 1N, P). This indicated that al-
though the diabetic state had a signiﬁcant negative impact on bone,
most of the variances in the data are contributed by antibody treatment.
Statistically, we ﬁnd a signiﬁcant antibody effect for all L4 bone parame-
ters measured, with or without diabetes. At 14 weeks, different parame-
ters show signiﬁcant diabetes × antibody interaction effects (Conn.
dens., SMI, and Tb. N.) that at 11weeks of age, suggesting that the syner-
gistic beneﬁts of antibody treatment on diabetic bone may change with
age or growth status. In cortical bone, BA/TA, BA, and BMDdid have a sig-
niﬁcant diabetic effect (Table 2). Antibody effects in SostAb STZ+ SostAb
mice increased BA/TA, BA, and BMD (all p b 0.001), compared with Con-
trol and STZ groups (Table 2). Thus, at 14 weeks of age in uninjured ani-
mals,we saw continued bone quality improvement after discontinuation
of SostAb treatment, in the absence of fracture.
4.3. SostAb treatment improves bone parameters in fracture callus of in-
jured STZ-treated mice
At 11 weeks of age, all groups had some amount of persistent carti-
lage in themid-callus regions examined (Figs. 2A, B–E). Both the SostAb
and STZ + SostAb groups appeared to have more mineralized bone
within the callus compared with Control and STZ groups (Figs. 2B–E).
At 14 weeks of age, bridging had occurred in all groups at the fracture
site, and remodelingwas evident by reduced trabecular bone in the cal-
lus region (Figs. 2F–I, compared with B–E). An enlarged marrow space
at the bridging site was evident in STZmice compared to Control, and
abundant adipocytes persisted (Figs. 2F,H, and arrowheads), while
both SostAb groups displayedmore bone at the site of fracture compared
with Control and STZ respectively (Figs. 2G,I).
Representative μCT reconstructions of calluses from 11-week old an-
imals are shown in Figs. 2K–N. Reconstructions were consistent with
histology, indicating a more porous bone structure in the calluses of
STZ mice compared with all other groups (Fig. 2M). SostAb-treated
groups (Figs. 2L,N) appeared to have thicker trabecular structure in cal-
luses compared with Control and especially STZmice (Fig. 2M). Quanti-
tative callus analysis by μCT conﬁrmed the histology (Table 3).
Compared with Controls, STZ calluses at 11 weeks of age had decreased
BV and TV, due to diabetic effects, indicating smaller fracture calluses,
but this resulted in similar BV/TV between the two groups. Bonemineral
content (BMC), the amount of mineralized bone per callus volume, had
a signiﬁcant diabetic effect, although the mean is unexpectedly higher
than Controls; this may be due to the reduced volume of the callus in
STZ animals. At 11 weeks of age, there was a signiﬁcant antibody effect
on all callus parameters except TV; and BMDhad a signiﬁcant diabetic ×
antibody interaction, which overall, reduced the BMD of the callus. An-
tibody effects on callus mineral suggested that SostAb treatment re-
duced BMD in the callus at relatively early healing stages.
By 14 weeks of age, the fracture calluses have matured. Diabetic ef-
fects on the callus at this stage are only seen in BMC and BMD
(Table 3, lower half), which reveals the long-term negative effects of di-
abetes on callus mineralization (p b 0.0001 for both parameters). Anti-
body effects on calluses at 14 weeks of age show signiﬁcant
improvements in BV/TV and BMC, indicating that SostAb treatment, re-
gardless of diabetic state, enhances mineralization or maturation of the
callus. Signiﬁcant gains in callus quality in STZ+ SostAb-treated animals
are retained at 14weeks of age, and themineralization of the callus had
reached or exceeded the level of Controls.
Fig. 1. SostAb treatment Improves low bonemass in STZ mice. Experimental design (A). Histological sections and stain with Alcian Blue and Nuclear Fast Red (B–M). The growth plate (B–E),
epiphysis (F–I), and cortex (J–M) represent the location of the cartilage, trabecular bone, and cortical bone respectively. Alcian Blue stains the cartilage in blue— see also yellow arrows (C, D, E).
STZmice showed some cartilage present also in the cortical bone (L, yellow arrow).White circles, indicated by black arrows (D,H, E) showadipocytes in the bonemarrow. The cortical bone (J–
M) shows degrees of cortical bone thickness (vertical arrows) in each group. Uninjured 11-week oldmicewere euthanized and the L4 vertebrae (N–Q) and distal femurs (R–U)were scanned
for uCT. L4 vertebrae uCT scans revealthat a visualized amount of trabecular bone is present within each group. A transverse plane on the distal uninjured femurs visually provides the differ-
ences of relative cortical bone thickness among each treated group. Calibration scale: bar = 100 μm.
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Table 1
Bone phenotyping based on μCT parameters in the cancellous bone compartment of the L4 vertebrae and cortical bone of uninjured 11-week old male mice compared with Controls.
Index Control (n= 6) SostAb (n= 6) STZ (n= 8) STZ+ SostAb (n= 8)
BV/TV (%) 0.235 ± 0.038 0.299 ± 0.006§ 0.177 ± 0.010⁎ 0.333 ± 0.028§❖
Conn. dens. (1/mm3) 326.203 ± 22.476 294.848 ± 23.435§ 288.401 ± 33.059 272.996 ± 22.562§
SMI (index [1]) 0.395 ± 0.219 0.32695 ± 0.030§ 0.8251 ± 0.101⁎ −0.114875 ± 0.214§❖
Tb.N. (1/mm) 5.490 ± 0.339 5.572 ± 0.165§ 5.191 ± 0.219 5.743 ± 0.319§
Tb.Th. (mm) 0.042 ± 0.004 0.055 ± 0.000§ 0.0350 ± 0.001⁎ 0.057 ± 0.003§❖
Tb.Sp. (mm) 0.172 ± 0.013 0.165 ± 0.007§ 0.183 ± 0.009 0.160 ± 0.011§
BMD (μg HA/cm3) 970.109 ± 14.809 963.635 ± 8.277 951.211 ± 18.037 967.104 ± 7.427
BA/TA (%) 0.393 ± 0.023 0.464 ± 0.020§ 0.308 ± 0.035⁎ 0.408 ± 0.026§
BA (mm2) 0.927 ± 0.131 1.143 ± 0.107§ 0.635 ± 0.123⁎ 0.909 ± 0.067§
TA (mm2) 2.349 ± 0.235 2.463 ± 0.184§ 2.052 ± 0.197⁎ 2.232 ± 0.123§
BMD (μg HA/cm3) 1062.294 ± 9.606 1067.389 ± 12.429§ 1049.428 ± 11.972 1069.487 ± 15.893§
Data represents mean ± standard deviation for parameters measured. BV = bone volume; TV = total volume; Conn. dens. = connectivity density; SMI = structural model
index; Tb. N = trabecular number; Tb.Th = trabecular thickness; Tb.Sp = trabecular separation; BMD = bone mineral density; TA = total area; BA = bone area.
§ p-Values b 0.05, antibody effect.
⁎ p-Values b 0.05, diabetic effect.
❖ p-Values b 0.05, diabetic × antibody interaction.
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repair
SP7/osterix, an early osteoblast marker (Figs. 3A–D), appeared dra-
matically elevated at 11 weeks of age, in STZ calluses (Fig. 3C, arrows),
with large numbers of positive cells aligned on the bone surface, sug-
gesting that lineage commitment and early osteoblast differentiation
were not inhibited in STZmice. However, Runx2, a pro-osteogenic tran-
scription factor that is increased early in the osteogenic differentiation
program (Figs. 3E–H), appeared reduced in STZ mice compared with
Controls (Figs. 3E,G), consistent with published results [41]. In STZ
mice, Runx2 stain was less plentiful compared with Controls, (Figs.
3E,G); treatment with SostAb did not increase the level of Runx2(Figs.
3E,F); STZ+ SostAb also did not appear to increase Runx2 levels com-
paredwith STZ calluses (Figs. 3G,H), collagen I, amatrix protein secreted
by osteoblasts (Figs. 3I–L) was visibly reduced in STZ calluses (Fig. 3K),
which indicated a decrease inmineralizedmatrix production consistent
with delayed or impaired osteogenesis (see also Table 3), while SostAb
and STZ + SostAb calluses showed increased levels (Figs. 3J,L), com-
pared with Controls (Fig. 3I). Osteocalcin (Figs. 3M–P) and DMP1
(Figs. 3Q–T), markers of osteoblast maturation and osteocyte differenti-
ation, appeared to have dramatically reduced signal in STZ calluses (Figs.
3O,S), which indicated delayed callus maturation in STZ calluses, while
Control (Figs. 3M,Q), SostAb (Figs. 3N,R), and STZ + SostAb (Figs. 3P,T)
groups revealed abundant signal along the surface of the bone. To deter-
mine if there is an alteration of cell apoptosis, activated caspase 3 anti-
body, an apoptosis marker (Figs. 3U–X), was stained on callus sections
at 11 weeks of age, revealing no visible change in signal between anyTable 2
Bone phenotyping based on μCT parameters in the cancellous bone compartment of the L4 ver
Index Control (n= 9) SostAb (n= 9
BV/TV (%) 0.223 ± 0.025 0.399 ± 0
Conn. dens. (1/mm3) 317.424 ± 32.066 335.117 ± 3
SMI (index [1]) 0.392 ± 0.193 −0.653 ± 0
Tb.N. (1/mm) 5.417 ± 0.274 6.265 ± 0
Tb.Th. (mm) 0.041 ± 0.003 0.067 ± 0
Tb.Sp. (mm) 0.177 ± 0.009 0.148 ± 0
BMD (μg HA/cm3) 969.230 ± 11.598 977.497 ± 1
BA/TA (%) 0.465 ± 0.015 0.565 ± 0
BA (mm2) 0.945 ± 0.094 1.084 ± 0
TA (mm2) 2.030 ± 0.190 1.920 ± 0
BMD (μg HA/cm3) 1121.596 ± 16.381 1146.834 ± 1
Data representsmean± standard deviation for parametersmeasured. BV=bone volume; TV=
trabecular number; Tb.Th = trabecular thickness; Tb.Sp = trabecular separation; BMD= bon
§ p-Values b 0.05, antibody effect.
⁎ p-Values b 0.05, diabetic effect.
❖ p-Values b 0.05, diabetic × antibody interaction.of the groups. Negative control stains for each antibody and antigen re-
trieval method are presented in Supp. Fig. 2. This suggests that cell apo-
ptosis was not contributing to poor bone in STZ calluses at 11 weeks of
age. At this time point, STZ+ SostAb calluses appeared to show patterns
for all markers similar to Controls or SostAb calluses, rather than STZ cal-
luses, which indicated a return to normal or better than normal healing,
based on marker representation of the healing process.
By 14 weeks of age, the callus had matured in injured Control ani-
mals, and SP7/osterix was still localized at the bone surface (Fig. 4A).
Collagen I appeared more abundant compared with 11 weeks of age
(Figs. 3I, 4E), and DMP1 protein was plentiful in Control calluses
(Fig. 4I). Compared with Controls, STZ calluses continued to have an
abundant number of SP7/osterix-positive cells lining the bone surface,
although not as plentiful as at 11weeks of age (Figs. 3C, 4C). STZ calluses
continued to have visibly reduced signal for collagen I compared with
Controls (Figs. 4E,G), which suggested a continued delay in mineraliza-
tion of the callus (see also Table 3). However, by 14 weeks of age, cells
that became embedded in bone matrix of STZ calluses produced
DMP1, at similar apparent levels compared with the other groups
(Figs. 4I–L). Antibody-treated groups at this time point appeared to
have more collagen I in the callus relative to Controls or STZ calluses
(Figs. 4E–H), which indicated possible enhanced mineralization. There
appeared to have been little impact of antibody treatment on the abun-
dance of DMP1 in the bony calluses of SostAb or STZ+ Sost Ab groups, as
all groups seemed to have similar levels (Figs. 4I–L).
While we did not see evidence of increased osteoblast apoptosis, we
considered that enhanced osteoclast activity in STZ diabetic bones could
contribute to fracture callus instability and poor bone structure. Wetebrae and cortical bone of uninjured 14-week old male mice compared with Controls.
) STZ (n= 9) STZ+ SostAb (n= 8)
.025§ 0.191 ± 0.027 0.403 ± 0.053§
4.703§ 282.650 ± 23.429 362.147 ± 55.315§❖
.208§ 0.601 ± 0.149 −0.844 ± 0.424§❖
.255§ 5.073 ± 0.263 6.350 ± 0.372§❖
.004§ 0.037 ± 0.003 0.065 ± 0.008§
.006§ 0.188 ± 0.011 0.149 ± 0.009§
2.198§ 955.274 ± 15.103 976.473 ± 20.533§
.0127§ 0.521 ± 0.034⁎ 0.439 ± 0.020§
.067§ 1.030 ± 0.138⁎ 0.771 ± 0.069§
.133 1.971 ± 0.155 1.757 ± 0.117❖
1.915§ 1123.519 ± 16.748⁎ 1117.314 ± 17.243§
total volume; Conn. dens.= connectivity density; SMI= StructuralModel Index; Tb. N=
e mineral density; TA = total area; BA= bone area.
Fig. 2.Histology andMicroCT reveals SostAb enhances endochondral healing. Histological sections on post-fracture (dpf) callus at 11 and 14 weeks of age were analyzed and observed at
themid regions (diagrams, A). Calluses at 11weeks of age (B–E) and14weeks of age (F–I)were sectioned and stainedwith AlcianBlue andNuclear Fast Red. AlcianBlue stains the cartilage
blue, easily observed in calluses of 11-week old mice (B–D). Adipocytes, indicated by black arrows (H, I) were observed in the bone marrow, easily seen in calluses of 14-week old mice.
Calluses at 11 weeks of age were also scanned for uCT, providing a visual illustration of the amount of woven bone present in the callus (K–N). Calibration scale: bar = 100 μm.
127C.S. Yee et al. / Bone 82 (2016) 122–134performed osteoclast-speciﬁc tartrate-resistant acid phosphatase
(TRAP) stain on uninjured bones and fracture calluses of 11-week old
animals, and did not ﬁnd any evidence of increased osteoclast activityTable 3
Bone phenotyping based on μCT parameters in the cancellous bone compartment of fracture c
Index Control (n= 6) SostAb (n= 6
BV/TV (%) 0.121 ± 0.014 0.206 ± 0
BV (mm2) 2.814 ± 0.496 4.368 ± 1
TV (mm2) 23.447 ± 4.642 21.473 ± 7
BMC (μg HA/cm3) 172.312 ± 5.433 253.603 ± 2
BMD (μg HA/cm3) 945.376 ± 15.143 905.870 ± 2
Index Control (n= 6) SostAb (n= 8
BV/TV (%) 0.286 ± 0.096 0.388 ± 0
BV (mm2) 1.797 ± 0.31 2.923 ± 0
TV (mm2) 6.831 ± 2.275 7.747 ± 2
BMC(μg HA/cm3) 373.075 ± 100.387 425.818 ± 7
BMD (μg HA/cm3) 1033.059 ± 32.891 1033.101 ± 2
Data represents mean± standard deviation for parameters measured. 11-week oldmouse frac
sented in the bottom half. BV = bone volume; TV = total volume; BMC = bone mineral conte
§ p-Values b 0.05, antibody effect.
⁎ p-Values b 0.05, diabetic effect.
❖ p-Values b 0.05, diabetic × antibody interaction.with this marker in the growth plate (Supp. Figs. 1A–D), epiphyseal tra-
becular bone (Supp. Figs. 1E–H), or fracture callus (Supp. Figs. 1I–L) of
STZ mice, nor did we see a change in TRAP activity with SostAballuses of 11-week old and 14-week old male mice compared with Controls.
) STZ (n= 6) STZ+ SostAb (n= 6)
.034§ 0.132 ± 0.0174 0.199 ± 0.039§
.543§ 1.841 ± 0.414⁎ 3.333 ± 1.258§
.424 14.429 ± 5.038⁎ 16.458 ± 3.638
5.708§ 204.106 ± 17.506⁎ 265.681 ± 33.555§
3.073§ 917.758 ± 4.496 908.803 ± 13.723§❖
) STZ (n= 7) STZ+ SostAb (n= 8)
.072§ 0.234 ± 0.037 0.366 ± 0.056§
.738 0.952 ± 0.349 2.75 ± 0.474
.67 4.088 ± 1.516 7.717 ± 1.516
0.307§ 279.438 ± 66.801⁎ 412.253 ± 53.769§
2.847 1004.713 ± 31.445⁎ 1010.653 ± 14.439
ture callus data are presented in the top half of the table, 14-week-oldmouse data are pre-
nt; BMD= bone mineral density.
Fig. 3. SostAb rescues abnormal osteoblast maturation in STZ observed by immunoﬂuorescence. Fluorescent immunostains on callus sections of 11-week old mice were completed with
markers of interest. Secondary antibodies of either green (Alexa Fluor 488) or red (Alexa Fluor 594) were used for detection and DAPI stains the nuclei of cells blue. An early osteoblast
marker, osterix, showed osteoblast residing along the surface of the woven bone as indicated by white arrows (A–D). An early osteoblast transcription factor, Runx2, is shown in panels
E–H. Collagen Type I, a protein secreted by osteoblasts, was shown in green within woven bone in panels I–L. A late osteoblast differentiation marker, osteocalcin, and osteocyte marker,
DMP1, are represented in panels M–P and Q–T, respectively. Apoptosismarker, activated caspase 3, is shown along thewoven bone and in the bonemarrow in panels U–X. Negative con-
trol slides, see Supp. Fig. 2. Calibration scale: bar = 100 μm.
128 C.S. Yee et al. / Bone 82 (2016) 122–134treatment. Additionally, we did not see a signiﬁcant difference in ca-
thepsin Kwhen tested by two-way ANOVA, whichwas used to examine
osteoclast maturity in epiphyseal bone and growth plate (Supp. Figs.
1M–Q). These data indicated that there is no difference in osteoclast ac-
tivity of STZ diabetic mice, 5 weeks after onset of diabetes (at 11 weeks
of age), and are consistentwith other reports of normal osteoclast activ-
ity in T1DM [3,10,11]. Our data indicated that osteoblast maturation
markers were reduced in STZ-diabetes, while we found no evidence of
osteoblast apoptosis or enhanced osteoclast activity to account for re-
duced bone mass; SostAb treatment of diabetic mice returned osteo-
blast marker levels to normal or enhanced levels.4.5. WNT signaling is diminished during diabetic fracture healing, and re-
versed with SostAb administration
To examineWNT signaling activity we assessed activated β-catenin
protein levels. In calluses of 11-week oldmice, very low levels of activat-
ed β-catenin were observed in STZ-treated samples (Fig. 5C). Control
calluses showed modest levels of activated β-catenin, primarily local-
ized to the bone-forming surface, with very fewpositive cells embedded
in the bone matrix (Fig. 5A). However, both SostAb-treated groups ap-
peared to have higher levels of activated β-catenin at the bone surface,
along with several positive cells in the bone matrix (Figs. 5B,D),
Fig. 4. SostAbanabolic effect during repair continued after treatment termination. Calluses inmice at 14weeks of agewere stainedwithmarkers of interest byﬂuorescent immunostaining.
Secondary antibodies of Alexa Fluor 488 (green) or Alexa Fluor 594 (red) were used for detection and DAPI stained the nuclei of cells blue. Osterix, an early osteoblast marker, signal was
along the surface of the bone as indicated by the white arrows (A–D). Collagen 1, a protein secreted by osteoblasts, appeared within the bone in panels E–H. DMP1, an osteocyte marker,
also appeared within the remodeling bone in panels I–L. Negative control slides, see Supp. Fig. 2. Calibration scale: bar = 100 μm.
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teoblasts. By 14 weeks of age, in calluses, we found moderate levels
of activated β-catenin in the bone of Controlmice, and it was no lon-
ger conﬁned to the bone-forming surface (Fig. 5I). STZmice appeared
to have small patches of activated β-catenin, but the signal was pri-
marily absent from osteocytes in the bone matrix (Fig. 5K). In SostAb
and STZ + SostAb-treated mice, 42 day calluses showed robust acti-
vated β-catenin signal throughout the callus (Figs. 5J,L), which
seemed to be increased over the levels seen in either Controls or
STZ calluses (Figs. 5I,L). These data demonstrated that SostAb admin-
istration elevated β-catenin activity, consistent with SOST's role as a
WNT antagonist [42].
When examining sclerostin levels in the callus at 21 days, we saw
modestly increased sclerostin in matrix-embedded cells of STZ mice,
compared with Controls, consistent with expression in osteocytes
(Figs. 5E,G).Wedid, however, observeddramatically increased sclerostin
protein levels in the bone of SostAb-treated groups (Figs. 5F,H). We also
observed increased activated β-catenin activity in these same groups
(Figs. 5B,D). By 42 days, we continued to ﬁnd increased sclerostin signal
in STZ calluses compared with Controls (Figs. 5M,O). We also found fur-
ther increased sclerostin localization in SostAb and STZ+ SostAb-treated
groups (Figs. 5N,P). We questioned whether we may have detected the
administered therapeutic SOST antibody, or whether we may have de-
tected sclerostin that is inactivated, but still found in bone. Our negative
control immunostains included secondary antibody stains against both
the rabbit antibody that was used to examine SOST in tissues (Supp.
Figs. 2A–D), and the mouse monoclonal therapeutic antibody that was
administered (Supp. Figs. 2E–H), under the same antigen retrieval condi-
tions.We foundno evidence of non-speciﬁc signal, or the ability to detect
the therapeutically administered antibody. Thus, we presume that the
high SOST signal detected in the tissue of antibody-treated mice is the
combined protein accumulation of biologically active SOST, and SOST
that is inactivated and bound to SostAb but still in tissues or circulation.
These ﬁndings were supported by the detection of elevated levels of
SOST in the serum. STZmice had a 30% increase in circulating sclerostin,
relative to Controls (p b 0.03) (Fig. 5Q). Circulating levels for sclerostin in
Controls were within the reported range for the assay. However, wefound 8 times the amount of circulating sclerostin in both antibody-
treated groups comparedwithControls (SostAb pb 5×10−9, STZ+ SostAb
p b 2 × 10−7). We ﬁnd a pattern of elevated SOST and decreased β-
catenin activity in the context of a high-glucose environment, while
SostAb treatment enhances β-catenin activity despite high SOST levels.
4.6. Enhanced bone marrow adiposity in healing fractures of STZ mice is
rescued by SostAb treatment
We saw some evidence that adipocytes are more abundant in the
marrow compartment of STZ diabetic mice, as has been suggested by
others, who have proposed that increased adipogenesis may be at the
expense of precursor differentiation into osteoblasts, resulting in re-
duced bone formation [43–45]. We additionally observed an up-
regulation of the number of adipocytes in the marrow after fracture,
compared with intact bone. To quantify the effects of diabetes on bone
marrow adiposity, we examined Masson's Trichrome-stained sections
from uninjured age-matched bones, and fracture calluses at 11 weeks
of age (Fig. 6). Total number of adipocytes per sagittal bone section
were analyzed for both sets of samples and compared by two-way
ANOVA. In uninjured bones we found a signiﬁcant effect of diabetes
on the adipocyte number (p b 0.001) (Fig. 6I), with no effect of antibody
treatment (Figs. 6A–D). However, in age-matched fracture calluses, we
saw an increase in marrow adiposity in all groups, which was dramati-
cally up-regulated in STZ diabetic mice (Figs. 6E–H). Quantiﬁcation of
the differences by two-way ANOVA revealed a signiﬁcant diabetic effect
in STZ mice, a signiﬁcant antibody treatment effect, and a signiﬁcant
diabetes × antibody interaction effect, suggesting that SostAb treatment
mitigates the enhanced adiposity seen in healing fracture callus of STZ
diabetic mice. SostAb treatment may in this way enhance fracture
healing by directly or indirectly reducing marrow adiposity, indepen-
dent of its effects on osteoblast maturation or activity.
5. Discussion
In this study, we treated fractured femurs in Type I diabetic mice
with SostAb to improve fracture healing outcomes. We utilized a
Fig. 5. Immunohistochemistry reveals altered Wnt signaling in treated groups. Fluorescent immunostains for β-catenin were stained on calluses at 11 (A–D) and 14 weeks of age (I–L).
Alexa Fluor 594 (red) was used as a secondary antibody while the cell nuclei were stained with DAPI. Beta-catenin signal is initially expressed along the surface of the bone (A–D) and
later within osteocytes during the remodeling stage (I–L). Sost antibody immunohistochemistry on calluses at 11 weeks of age (E–H) and 42 dpf calluses (M–P) is expressed with the
woven bone and osteocytes during the later stages of healing. Sost serum levels in each treated group was measured using an ELISA kit for mouse Sost (Q) and represented in ng/mL.
p-Values b 0.05 are statistically signiﬁcant (asterisks), compared with controls. Negative control slides, see Supp. Fig. 2. Calibration scale: bar = 100 μm.
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growing mice. Consistent with previous reports, STZ-treated mice lose
bone mass and quality within 3 weeks of becoming diabetic [47,48].
The STZmouse model we report here results in mild osteopenia, similar
to T1DM patients [17]; however, it does not represent a true model of
T1DM, as there is no auto-immune trigger for the disease, so not all po-
tential impacts of T1DM can be examined in this context. STZ-induced
diabetes, at the dose we report here, has been reported as an appropri-
ate model for T1DM effects on bone and are similar to spontaneous
models of T1DM [10]. The loss of bone we report here is primarily
based on reduced bone formation, as we saw reduced mineral deposi-
tion, which was conﬁrmed by immunoﬂuorescence for matrix markersand μCT, andwe did not ﬁnd evidence of enhanced osteoclast activity in
either uninjured bones or fracture calluses in our model.
We found that SostAb treatment of STZmice dramatically enhanced
bone formation, but despite the dramatic increases in bone volume,
mineral density did not increase comparedwithControls. This suggested
that SostAb in the diabetic setting may function to promote osteoblast
differentiation or osteoblast activity, and allows mineralization to
catch up to normal levels. This is evidenced by the fact that neither
SostAb nor STZ + SostAb had bone mineral densities at the end of the
study that exceed the levels of Controls, while densities of both groups
were less than Controls after 3weeks of treatment. However, SostAb ap-
pears to enhancemineralization of fracture calluses and thus potentially
Fig. 6. Histology reveals increased adipogenesis in STZ mice that is reversed with SostAb treatment. Masson Trichrome stains (collagen, red; nuclei, black; bone, blue; cartilage, white;
adipocytes, empty circles) on uninjured bone sections and fracture callus at 11 weeks of age indicated increased marrow adiposity in STZmice without injury (A–D, I). During fracture
healing, adipogenesis increased in themarrowof all groups, but substantially in STZ calluses (E–J). Two-wayANOVA demonstrated a diabetic effect in uninjured animals (I), and in fracture
calluses, there was a diabetic effect, an antibody effect, and a diabetes × antibody interaction effect. *p b 0.05, diabetic effect. §p b 0.05, antibody effect. ❖p b 0.05, diabetes × antibody in-
teraction. Calibration scale: bar = 500 μm.
131C.S. Yee et al. / Bone 82 (2016) 122–134improve the strength of newly repaired bone, as SostAb treatment re-
sulted in dramatically enhanced bone mineral content of callus at
14 weeks of age in both normal and diabetic mice. Similarly, recent re-
ports have demonstrated reduced mineral content of bone after SOST
antibody treatment, or due to genetic loss of Sost, despite abundant
bone formation [48,49]. It is likely that reduction of SOST via antibody
treatment increases osteoblast activity to produce abundant osteoid,
which then mineralizes at a normal rate. At later time points, this
leads to higher mineral content in the abundantly formed new bone,
thereby potentially increasing mechanical stability. Furthermore, early
reports that successfully used SOST antibody treatment to promote frac-
ture healing relied heavily on models that primarily healed by
intramembranous bone formation [34,35,50,51]. This suggested that
SostAb may be beneﬁcial in problematic fracture healing that results
from poor osteogenesis; however, Li et al., [52] reported fracture repair
in an endochondralmodel in Sost−/−mice, and Feng et al., [53] reported
similar results with SOST antibody treatment, suggesting that fracture
repair may beneﬁt from early intervention by reducing sclerostin levels,
rather than only during osteogenesis. While we found a signiﬁcant
beneﬁt in callus BV and BV/TV of STZ+ SostAbmice, we also saw an in-
crease in callus size, suggesting a beneﬁt in early repair events prior to
osteogenesis.
The large number of osteoblasts and precursors at the bone surface
that show SP7/osterix, in the absence of signiﬁcant mineral, suggests
that the osteopenia in STZ diabetic mice may be due to a defect in oste-
oblast maturation andmatrix synthesis. In another report, STZmice had
the same amount of immature mesenchymal tissue but decreased oste-
oblast differentiation. This was associatedwith decreased collagen Type
1, and Runx2 mRNA expression in an intramembranous bone repairmodel [54], similar to our ﬁndings. Song et al., [55] demonstrated that
loss of β-catenin in osteoblast precursors results in a switch from oste-
ogenesis to adipogenesis that causes low bone mass. As our STZ mice
displayed increased adiposity in themarrow, this is a plausible explana-
tion for impaired osteogenesis in our STZ mice. SOST is not known to
regulate the cell fate of precursor cells, however, our study shows evi-
dence that adipogenesis dramatically increases during callus formation.
This suggested that a pool of precursors have recently differentiated,
and SostAbmitigated this effect, leaving open the possibility that elevat-
ed Wnt signaling inﬂuences the fate of precursor cells.
Furthermore, STZmice appear to have much less osteocalcin at the
bone surface, indicative of immature osteoblasts. However, reduced
osteocalcin has also recently been implicated inmetabolic activity of os-
teoblasts, in which reduced insulin signaling in osteoblasts and reduced
Runx2 expression may fail to activate osteocalcin to promote local and
systemic metabolic homeostases in STZ diabetes [56]. In STZ diabetic
mice, osteoblasts are no longer able to depend on glucose as an energy
source, but must rely on lipid metabolism to generate ATP [56]. LRP5,
aWnt co-receptor, has been implicated in this process, andmice lacking
Lrp5 develop metabolic imbalance with increased adiposity. We have
shown that SOST primarily inhibits LRP5-dependent Wnt signaling
[27], thus in the absence of insulin, SostAb may restore Wnt signaling
through LRP5 to partially re-balance metabolic homeostasis, indepen-
dent of glucose metabolism. In this way, metabolic stress on the osteo-
blasts is relieved, and differentiation andmetabolism can proceedmore
normally.
Another STZ diabetic model showed that in T1DM, insulin and IGF-1
deﬁciency decreases osteogenesis due tonegative regulation ofWnt sig-
naling activity [11]. It was demonstrated that the decreased bone
132 C.S. Yee et al. / Bone 82 (2016) 122–134formation was caused by reduced levels of activated β-catenin, precipi-
tated by a loss of phosphorylated GSK3β, and phosphorylated AKT/PKB,
targeting β-catenin for degradation. They also observed a dramatic in-
crease in WNT inhibitor (Sost and Dkk1) levels. Loss of phosphorylated
AKT/PKB can occur from a cycle of reduced WNT signaling, as in the
presence of high SOST levels, or in the event of oxidative damage. As a
result, cells (such as osteoblast precursors and early osteoblasts) in a
low insulin, high SOST, high glucose (oxidative) environment may be
subject to cell cycle arrest [57,58]. Another study observed a decrease
in cyclin DmRNA expression in osteoblast cells treated in a high glucose
environment [59], which correlated with increased apoptosis and re-
duced cell proliferation. Taken together, these ﬁndings may account
for the reduced number of Runx2-positive cells, and/or the apparent in-
hibition of differentiation of osterix-positive cells seen in our STZmice.
Whilewe did not observe enhanced activated caspase-3-driven apopto-
sis in calluses at 21 days, it is possible that early osteoblast or precursor
death at another time point may contribute to reduced osteogenesis in
our T1DM model.
Reports are conﬂicting on whether T1DM induces changes in osteo-
clast activity, with some studies reporting enhanced, unchanged, or
even reduced osteoclast activity in the context of T1DM. Reports of
osteopenia compared with osteoporosis in T1DM are difﬁcult to
deconvolute, and are likely due to differences in age of animals or pa-
tients, time since diagnosis, diabetic complications (such as vascular or
kidney disease), and body condition [3,4,7]. We found no change in os-
teoclast activity, which is consistent with the recent time since diagno-
sis and young age of our study groups.
Oxidative stress in tissues leads to much of the destructive sequelae
in diabetic patients, causing pancreatic beta-cell death, kidney disease,
cardiovascular disease, and may contribute to the effects of diabetes
seen in the skeleton [60]. Reduced WNT signaling and increased WNT
antagonism have been associated with increased oxidative stress, and
reduced osteoblast activity [11,61,62]. Oxidative stress activates FOXO
signaling, which competes for β-catenin in the cell, to reduce activation
ofWNT target genes. Activation ofWNT signaling activates the AKT/PKB
pathway; PKB then phosphorylates and sequesters FOXO in the cyto-
plasm, and prevents it from competing with β-catenin [63]. As SOST is
an antagonist of β-catenin-mediatedWNT signaling, reduction of bioac-
tive SOST through SostAb treatment activates β-catenin signaling, po-
tentially mitigating the effects of oxidative stress and competition by
activated FOXO [61]. Thus, WNT signaling may be suppressed by a
mechanism that is independent of SOST, but can be mitigated by pro-
moting WNT signaling through inhibition of SOST. In this way, SostAb
can alleviate the effects on diabetic bone that cannot be overcome by
treatment with insulin.
We examined sclerostin and β-catenin levels in ourmice, to demon-
strate that SostAb is effective at suppressing sclerostin activity and ele-
vatingWNT signaling activity through activation ofβ-catenin.We found
elevated sclerostin in serum, and decreased activated β-catenin in STZ
mice, consistent with other reports of diabetic animals and patients
with elevated SOST levels [9,11,24,61]. While we did ﬁnd elevated β-
catenin in antibody-treated groups, consistent with elevated WNT sig-
naling and promotion of osteogenesis, we also saw an unexpected and
very highly elevated level of sclerostin protein in the bone and blood
of antibody-treated animals. This ﬁnding was unexpected, but there
has been a recent report of sclerostin-antibody treatment associated
with elevated expression of sclerostin [64]. At these extreme levels of
SOST protein we ﬁnd in the serum and bone, however, it is likely that
the majority of the protein is inactivated by antibody bound to it.
SOST antibody has been reported to have a very long lifespan in circula-
tion; Ominsky et al.[65] reported SOST antibody levels in circulation of
cynomolgus monkeys and found that a single dose can be detected in
circulation up to nearly amonth post-dose,while Padhi et al.[66] report-
ed a single dose detected in serum up to an amazing 85 days after a sin-
gle dose. In addition, it has been reported that SostAb bound to
sclerostin prevents internalization of sclerostin and Wnt inhibition bysclerostin, similar to our ﬁndings in vivo [67]. These results pose some
questions that remain unanswered: SostAb bound to sclerostin may
have a very long lifespan in tissues; are high therapeutic doses of anti-
body needed to combat elevated expression and protein levels in re-
sponse to treatment? Furthermore, sclerostin bound to SostAb may
prevent degradation of eithermolecule, revealing a need to study down-
streameffects of this protein construct,which appears to be in circulation
for extended periods of time. Future experiments are needed that exam-
ine the long-term effects of SostAb treatment on osteoblast metabolism;
these experiments can be conducted in Ins2(Akita) mice, as they become
diabetic by a nearly identical mechanism to STZ-induced diabetes, and
have a much longer lifespan in the diabetic state. These studies have
the potential to uncover more mechanistic insight into the interaction
between the diabetic state and Lrp5-dependent/Sost-mediated osteo-
blastmetabolism, and the contribution towhole bodymetabolic homeo-
stasis. The phenotype of these mice is penetrant in both genders, which
will facilitate much-needed studies in female animals.
6. Conclusions
Our study has revealed that anabolic doses of SostAb enhance bone
formation and quality in an early-onset Type I diabetic fracture healing
model. We provide evidence that SostAb alleviates inhibition on osteo-
blast differentiation caused by the diabetic state. We further demon-
strated that the effects of SostAb treatment may extend well beyond
the end of the dosing regimen, since our result show continued im-
provement of bone parameters in STZ diabetic mice treated with anti-
body, even three weeks after treatment had stopped. We observed
SostAb-mediated reduction of marrow adiposity during callus forma-
tion, whichmay be of signiﬁcant therapeutic beneﬁt in diabetic fracture
healing. We also uncovered an as yet undocumented in vivo phenome-
non of apparent accumulation of sclerostin and/or sclerostin-antibody
complexes as a result of treatment, which is worth further exploration.
In summary, SostAb is an effective treatment to counteract the low os-
teogenesis that occurs in T1DM bone environments, and may provide
extended beneﬁts beyond the treatment span.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2015.04.048.
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